Akari Therapeutics (NASDAQ:AKTX) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a strong sell rating to a sell rating in a research note published on Saturday.

A number of other analysts have also commented on the stock. Maxim Group upgraded shares of Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research note on Monday, July 20th. Weiss Ratings raised shares of Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Akari Therapeutics Price Performance

Shares of NASDAQ:AKTX opened at $7.85 on Friday. Akari Therapeutics has a fifty-two week low of $3.02 and a fifty-two week high of $49.60. The business has a 50-day simple moving average of $9.93 and a two-hundred day simple moving average of $8.96.

Institutional Trading of Akari Therapeutics

An institutional investor recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC bought a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics as of its most recent filing with the Securities & Exchange Commission. 5.06% of the stock is owned by hedge funds and other institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.